Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Plus Therapeutics ( (PSTV) ) just unveiled an announcement.
On January 22, 2026, Plus Therapeutics updated its corporate presentation for investors, outlining an intensified strategic focus on CNS cancers, an area where metastases now outnumber primary brain cancers by roughly ten to one and survival improvements have lagged for decades. The company highlighted CNSide as a “best-in-class” diagnostic for CNS metastases, backed by prior use at 120 U.S. institutions and recent national coverage agreements with major insurers, and detailed its lead radiotherapeutic candidate REYOBIQ, which is in multiple mid-stage ReSPECT clinical trials for leptomeningeal metastases and recurrent glioblastoma and is designed to deliver up to 20 times more radiation than standard therapies while bypassing the blood–brain barrier. By combining improved diagnostics, precision radiotherapeutics, and unified data analytics, Plus Therapeutics is seeking to create a new treatment “playbook” for CNS oncology, with the goal of materially extending median overall survival in leptomeningeal metastases and strengthening its competitive positioning in the growing CNS cancer market.
The most recent analyst rating on (PSTV) stock is a Hold with a $0.28 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
Spark’s Take on PSTV Stock
According to Spark, TipRanks’ AI Analyst, PSTV is a Neutral.
The score is primarily held down by weak financial performance—large ongoing losses, significant cash burn, and volatile/declining revenue—suggesting elevated funding risk. Technical indicators reinforce the downside trend (price below key moving averages with negative MACD), while valuation is difficult to support due to negative earnings and no dividend yield.
To see Spark’s full report on PSTV stock, click here.
More about Plus Therapeutics
Plus Therapeutics, Inc. is a Nasdaq-listed oncology company focused on central nervous system (CNS) cancers, developing both diagnostics and radiotherapeutics. Its key products include CNSide, a diagnostic platform for CNS metastases with a U.S. commercial relaunch planned for the third quarter of 2025 and a target market of roughly 500,000 patients annually, and REYOBIQ, a first-in-class targeted radiotherapeutic for CNS cancers with FDA Fast Track and Orphan Drug designations. The company is positioning itself around a fully integrated CNS platform that combines CNSide’s cellular and molecular data with REYOBIQ’s imaging and delivery data to improve survival outcomes in leptomeningeal metastases and other CNS cancers, targeting a total addressable market exceeding $22 billion.
Average Trading Volume: 7,553,157
Technical Sentiment Signal: Sell
Current Market Cap: $50.87M
Learn more about PSTV stock on TipRanks’ Stock Analysis page.